Acadia Pharmaceuticals Sells Rare Pediatric Priority Review Voucher for $150M to Fuel CNS and Rare Disease R&D

Acadia Pharmaceuticals (Nasdaq: ACAD) has announced an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million. The PRV was awarded to Acadia in March 2023 after the FDA approved DAYBUE™ (trofinetide) for treating Rett syndrome, a therapy licensed from Neuren Pharmaceuticals. Per their agreement, Acadia will pay Neuren one-third of the net proceeds.

Proceeds from the PRV sale will be used to support Acadia’s commercial operations, R&D in central nervous system and rare diseases, and potential future business development. The transaction is subject to customary closing conditions, including the expiration of the Hart-Scott-Rodino waiting period. Jefferies LLC advised Acadia on this deal.

The company will announce Q3 results today, November 6 after the market close.